Trial Profile
Phase I- II Study of in Vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus With or Without Vidaza (Azacitidine) for the Treatment of Steroid-refractory Acute Graft-versus-host Disease
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 04 Mar 2022
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Interleukin-2 (Primary) ; Cyclophosphamide; Sirolimus
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Acronyms T-REG
- 04 Feb 2022 Status changed from completed to discontinued.
- 01 Jul 2012 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 01 Jul 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.